Dr Nicholas Short speaks to ecancer at the ASH 2019 meeting in Orlando about a phase II trial using inotuzumab ozogamicin and low-intensity chemotherapy with or without blinatumomab in patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia (ALL).
Dr Short explains that the co-primary endpoints were to evaluate the response rate and overall survival. He reports that both endpoints showed improvement over historical results, but noted that the 60-69 age group showed more benefit compared to the 70 and over age group. Dr Short concludes by describing what these results mean for the next steps of the study.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.